The current invention is most widely in the field of molecular biology, more particularly in the field of virology and provides a means for introducing changes into a genome of a eukaryotic cell, which may be duplications, multiplications, insertions, deletions, inversions and/or translocations of a DNA sequence.
Papillomaviruses are small species-specific DNA tumor viruses that establish latent infection in the basal cells of the differentiating epithelium with the help of viral oncoproteins and maintain their small, about 8 kb, circular doublestranded (ds) genomes as episomal multicopy nuclear plasmids in proliferating transformed cells (Howley and Lowy, 2001) via action of the viral replication proteins E1 and E2 (Ustav and Stenlund, 1991; Chiang et al., 1992; Sverdrup and Khan, 1994). The E1 protein is the replication origin recognition factor and viral helicase (Yang et al., 1993; Sedman and Stenlund, 1998), which in cooperation with E2 facilitates recognition and effective loading of the host cell replication complexes at the papillomavirus origin in the upstream regulatory region (URR) (Ustav et al., 1991, 1993; Remm et al., 1992; Russell and Botchan, 1995; Stenlund, 2003).
In the latently infected basal cells, the high-risk (HR)-HPV genomes persist as episomal multicopy circular nuclear plasmids in order to support the viral life cycle. However, coexistence of the integrated and the episomal forms of HPV DNA in the same cells has been reported (Cooper et al., 1991; Kristiansen et al., 1994; Alazawi et al., 2002; Peitsaro et al., 2002a, b; Andersson et al., 2005; Arias-Pulido et al., 2006; Kulmala et al., 2006; Pett et al., 2006). The trigger for HPV integration is unclear, but linear fragments generated by dsDNA breaks of the genome or by ‘onion skin’ type of defective viral replication mode (Männik et al., 2002) may serve as substrates for integration (
Cells carrying integrated HR-HPV sequences have selective growth advantage due to the increased cell immortalization (Romanczuk and Howley, 1992; Jeon et al., 1995). In the case of HPV18, HPV31 and HPV35, nearly 100% of the viral sequences show integration into the cancer cell genome. Integrated and episomal viral genomes are commonly found in the HPV16 DNA-positive cancers (Cooper et al., 1991; Kristiansen et al., 1994; Peitsaro et al., 2002a, b; Andersson et al., 2005; Arias-Pulido et al., 2006).
The papillomaviruses do not follow once-per-cell cycle replication mode (Ravnan et al., 1992; Piirsoo et al., 1996); therefore, multiple unscheduled initiation events at the functional integrated HPV origin could extend into the adjacent genomic locus and trigger rearrangements like deletions or duplications of the sequences of the cellular genome by repair/recombination machinery.
The present invention is based on the ability of the HPV genome including its replication origin sequence to start DNA replication in two directions from the location of the replication origin sequence in the presence of HPV early proteins, in particular the E1 and E2 protein of various HPV strains. The authors have studied the events that may contribute to the formation of invasive cancers in the case of HR-HPV infections by demonstrating the effective HPV E1- and E2-dependent DNA amplification of the integrated HPV18 and HPV16 origins in HeLa and SiHa cells, respectively. The replication forks initiated at the integrated HPV origins extend into the flanking regions of cellular DNA. These amplified genomic sequences, resembling ‘onion skin’-type DNA replication intermediates as targets for the recombination and repair system that causes excisions of these sequences, resulting in de novo rearrangements and recombinations within the cellular DNA.
In result single-stranded or double-stranded DNA fragments were generated. These fragments possess biological activity. The fragments may be used as antisense DNA, DNAzyme or decoy-DNA. Moreover, any kind of these fragments may be used for therapeutical applications.
The integrated HR-HPV origin is effectively mobilized for replication by E1 and E2 produced from respective expression vectors, and from episomal HPV genomes transiently replicating in these cells. As a result, amplification of the integrated HR-HPV genome and flanking cellular DNA sequences occurs (
Also de novo infection of papillomaviruses could result in intracellular mixture of episomal and integrated HPV and subsequent amplification of integrated HPV DNA together with flanking cellular sequences (
We can call it ‘hit-and-run’ mechanism as ‘lowrisk’ or ‘high-risk’ HPV episome itself could be lost quickly after the infection, but the damage caused by the chromosome-associated HR-HPV amplification remains.
The presented data suggest that papillomavirus DNA replication machinery can actively induce irreversible changes in the genomic make-up of the cell at sites of HPV origin integration. The results show that papillomavirus replication proteins are capable of mobilizing integrated HPV origin and that simultaneous DNA replication of episomal and integrated HPV origins may occur in HeLa cells. These kinds of changes provide a useful tool for research, if one wishes to amplify, excise or translocate a genomic sequence, either adjacent to the integration site of the HPV sequence or wishes to introduce foreign sequences to the cell with respectively constructed HPV vector. The kit including HPV replication origin and overexpression of genes encoding HPV E1 and E2 for introducing duplications, multiplications, insertions, deletions, inversions and/or translocations of a DNA sequence into a eukaryotic cell is particularly important as it exhibits unexpectedly good viability of the transfected cells thus making the system a good model for in vivo experimentation. Moreover, amplification of a DNA sequence encoding functional units of heredity allows this combination to serve as basis for gene expression and overexpression experiments. The beforementioned kit comprises a vector carrying HPV genome or a part of HPV genome including HPV replication origin sequence, and expression vector or vectors encoding HPV early proteins, e.g. E1 and E2.
(A, B) HeLa cells were cotransfected with plasmids for expression of homologous E2 and E1 from HPV6b (lanes 1-4), HPV11 (lanes 5-8), HPV16 (lanes 9-12) and HPV18 (lanes 13-16) together with 0.5 μg of pUCURR-6b, -11, -16 and -18, respectively. As controls, either 5 μg pMHE1-18 and 5 μg pQMNE2-18 (lanes 17 and 18) or 0.5 μg pUCURR18 alone (lanes 19 and 20) was transfected. A 3 μg measure of total DNA extracted 24 and 48 h after transfection was digested with HindIII/DpnI and analyzed by Southern blotting with radiolabeled pUC probe (A) or all four HPV URR sequences (B). (C) Schematic presentation of the HPV6b, -11, -16 and -18 E1 expression constructs. (D) Analysis of expression of HA epitopetagged E1 of HPV6b (lanes 1 and 2), HPV11 (lanes 3 and 4), HPV16 (lanes 5 and 6) and HPV18 (lanes 7 and 8) 48 h after transfection with 3F10-HRP antibody. (E) Schematic representation of the episomal HPV18 genome and the integrated HPV18 in HeLa cells (Lazo, 1987; Meissner, 1999). Cellular DNA is shown as dashed line and HPV18 DNA as solid line. Open arrows represent the viral ORFs and noncoding URR shown as an open box.
(A, E) Increasing amounts of HPV18 E1 expression plasmids (from 0.5 to 10 μg) were cotransfected with 1 μg of HPV18 E2 expression vector. Total cellular DNA was extracted 24 h and 48 h after transfection and 3 μg of DNA was digested with HindIII (A) or BamHI (E) and analyzed by Southern blotting with 32P-labeled HPV18 URR probe. (B) Southern blot analysis of HeLa cells transfected with HPV18 E1 vector (5 μg) and an increasing amount of HPV18 E2 vector (0.5-10 pg). DpnI was used to remove input plasmids. (C) Western blot analysis of HPV18 E1 protein expression in HeLa cells 48 h after transfection with 3F10-HRP antibody. (D) Western blot analysis of HPV18 E2 protein with 4E4 antibody. (E) Total cellular DNA was extracted at various time points from cells transfected with 1 μg pQME2-18 and 10 μg pMHE1-18 (lanes 1-6) or from mock-transfected cells (lanes 7-12); 3 pg from each DNA sample was digested with BamHI/DpnI and subjected to Southern blotting analysis with 32P-labeled HPV18 URR-specific probe.
(A) Schematic presentation of the integrated HPV16 genome in chromosome 13 in SiHa cells. Viral ORFs are shown as open arrows and URR is indicated by an open box. Numbers in italics indicate the nucleotides of viral genome at the junction with cellular DNA. Acc65I restriction sites at nt 880 and nt 5378 of the viral genome are shown (B) SiHa cells were transfected. with expression vectors for E1 and E2 as follows: 2.5-20 μg of HPV6b E1 (lanes 1-4); 2.5-20 μg of HPV11 E1 (lanes 5-8); 1.2-5 μg of HPV16 E1 (lanes 9-11) and 1.2-5 μg of HPV18 E1 (lanes 10-12). A 5 μg measure of homologous E2 expression vectors was added for each transfection. For controls, either 5 μg pMHE1-16 alone (lane 13) or 5 μg pQMNE2-16 alone (lane 14) was transfected into the cells. The total DNA was isolated 24 h after transfection and 3 pg was digested with Acc65I/DpnI and analyzed by Southern blotting using radiolabeled HPV16 URR probe. (C) Analysis of E1 protein expression in SiHa cells 24 h after transfection using Western blot.
(A) Graphical representation of amplification of HPV16 URR and flanking sequences of two independent experiments, as described in (B). A 5 μg portion of pMHE1-16 and 5 μg pQMNE2-16 (dashed line in panel A and second row in panel B) or 5 μg pMHE1-18 and 5 μg pQMNE2-18 (solid line in panel A and third row in panel B) were transfected into SiHa cells. A 3 pg portion of total cellular DNA was extracted 24 h after transfection, digested with different enzyme combinations (indicated at the top in panel B, restriction sites shown in panel A) and then subjected to Southern blot analysis. Filters were probed with either radiolabeled HPV16 URR (lane 3 in panel B) or with cellular sequences (panel B, lanes 1, 2, 4 and 5) from various distances from both sides of the viral integration (SL1, SL2, SR1 and SR2). The replication signals were quantified on PhosphorImager and normalized to the signal from the mock-transfected SiHa cells. The average increase in copy numbers of different sequences is calculated (shown by vertical italic numbers in the graph in panel A). (C) Graphical representation of the results from two independent experiments, where 5 μg pQMNE2-18 together with increasing amounts of pMHE1-18 (2.5 μg, dotted line; 5 μg, dashed line; 10 μg, solid line) was transfected into SiHa cells. The replication signals were analyzed as described above and the average copy numbers corresponding to different sequences (URR-16, SL1, SL2, SR1, and SR2) are shown in the table (D).
(A) Low-molecular-weight DNA was extracted from HeLa cells at 48 and 96 h after transfection and (B) total DNA isolated from transfected HeLa cells at 48 h was analyzed by Southern blotting. A 3 μg portion of pUCHPV18 alone (lanes 2 and 3 in panel A and lane 1 in panel B), together with 10 μg pMHE1-18 (lanes 4 and 5 in panel A and lane 2 in panel B) or 10 μg pMHE1-18 and 2.5 μg pQMNE2-18 (lanes 6 and 7 in panel A and lane 3 in panel B), was transfected into HeLa cells. As controls, HeLa cells were transfected with 1 μg pUC-URR18 and 10 μg pMHE1-18 (lanes 8 and 9 in panel A and lane 4 in panel B), or together with 2.5 μg pQMNE2-18 (lanes 10 and 11 in panel A and lane 5 in panel B). A 5 μg portion of total DNA or half of the material from 60 mm dish (in case of low-molecular-weight DNA) was digested with HindIII/DpnI followed by Southern blot analysis with labeled HPV18 URR probe. Mock transfections (lane 1 in panel A and lane 6 in panel B) as well as 100 pg of HindIII-digested pUCHPV18 and pUC-URR18 are shown (lane 12 in panel A and lane 7 in panel B). (C) Southern blot analysis of the total population (lane 2) and sorted GFP-positive cells (lane 3) cotransfected with 10 pg pUCHPV18 plasmid and 0.5 μg pEGFP-N1. Sample from mock transfection is shown in lane 1. Markers of pUCHPV18 plasmid are shown in lanes 4-7; numbers indicated in the figure correspond to the copy number per cell. The total cellular DNA was extracted 48 h after transfection and 1.6 μg of it (corresponding to 2.5×105 diploid cells) was analyzed in each lane as described above. The results from two independent experiments are presented in (D).
(A) Southern blot analysis of subclones from SiHa cells transfected with 10 μg pMHE1-16 alone (upper panel, lanes 1-43) or together with 5 μg pQMNE2-16 (lower panel, lanes 1-44). Single cell subcloning was performed 72 h after transfection. Total cellular DNA was extracted from each subclone and 3 μg of DNA was digested with BamHI and analyzed by Southern blot with radiolabeled HPV16 URR probe. Total DNA samples from SiHa cells were used for control (lane 44, upper panel; lane 45, lower panel). (B) HindIII, BglII and BamHI restriction analysis of subclones with rearrangements. Restriction pattern of control cells is shown in lanes 25-27. (C) Restriction map of SiHa chromosome 13 close to the HPV16 integration site. Lengths of the appropriate restriction fragments between two sites are depicted in parentheses. (D) Schematic representation of rearrangements at the HPV16 integration site in the third subclone as determined by DIPS-PCR. See Supplementary data for DNA sequence.
Papillomavirus DNA is designated with −, host cell DNA is designated with = and different regions designated with -x-.
Titration of the HPV18 E1 and E2 proteins in the transient assays showed that the efficiency of DNA replication initiation depends on the E1 protein concentration (
To test E1 expression constructs and to identify the conditions conducive to viral origin replication, the origin plasmids (pUC/URRs) of all HPVs, together with the homologous expression vectors for E1 and E2, were cotransfected into HeLa cells. The DpnI resistant replication signal from the transient assays was examined by Southern blot analysis of total DNA with common plasmid probe (
SiHa cell line derived from the cervical carcinoma of a 55-year-old Japanese female is aneusomic and has been found to contain 66-72 chromosomes. However, this cell line has been shown to be disomic with respect to chromosome 13, which contains one copy of the HPV16 genome (Meissner, 1999; Szuhai et al., 2000). Integration of the HPV16 genome has occurred, with disruption in the E2 and E4 ORFs at nucleotides 3132 and 3384 of HPV16 genome (
The replication competence of the integrated HPV origins directed by viral replication proteins brings up an intriguing possibility that flanking cellular sequences on both sides of viral integration could be coamplified. We determined the size of the replicon also in SiHa cells by measuring the amplification levels of cellular sequences at various distances from integrated viral DNA replication origin. The HPV16 genome is integrated at chromosome 13q21-31 in SiHa cells. The integrated HPV16 as well as the flanking cellular DNA have been sequenced (Baker et al., 1987; Meissner, 1999). The 50 and 30 flanking cellular DNA sequences, determined by Baker et al., were subjected to BLAST search against the NCBI 36 assembly of human genome (released in November 2005). According to the results, 50 viral-cellular junction in SiHa was located at 72 686 871 by and 30 viral-cellular junction at 72 984 815 by of chromosome 13. This suggests that the distance between these junctional sequences is normally approximately 300 kb, indicating that considerable loss of genomic DNA has taken place in the process of integration of HPV16 DNA. Coordinates of the viral-cellular junctions, determined by BLASTsearch, were used to identify and amplify cellular sequences at various distances from integrated HPV16 using PCR. Sequence blocks with the furthermost nucleotide at 5.4 and 12.6 kb upstream (SL1, SL2 in
HeLa cells were transfected with the plasmid carrying functional full-size HPV18 genome cloned into pUC19 plasmid. Extrachromosomal supercoiled plasmids from the transfected cells were extracted at certain time points by alkaline lysis. Analysis of the episomal replication products (provided in
Amplified HPV locus in SiHa cells is the potential target for repair/recombination machinery that may result in chromosomal alterations. The cells transfected with low amounts of HPV16 E1 and E2 expression plasmids were single cell subcloned 72 h after transfection. The subclones were expanded, total DNA was extracted and purified, and the HPV16 integration patterns of subclones were analyzed by Southern blot analysis using URR probe. Alterations in the restriction pattern of the integrated HPV16 locus could be detected only in cases when at least one of the cleavage sites for specific restriction enzyme is outside of the DNA fragment that was involved in rearrangement. Therefore, BamHI cleavage, which generates 21.5 kb DNA fragment from 1.8 kb upstream to B20 kb downstream of HPV16 URR, was used (
It is believed that the methods and examples shown or described above have been characterized as preferred, various changes and modifications may be made therein without departing from the scope of the invention as defined in the following claims.
Plasmids
Plasmids pQMNE2-6b, -11, -16 and -18 were prepared by cloning E2 ORFs from HPV6b (2723-3829 nt), -11 (2723-3826 nt), -16 (2756-3853 nt) and -18 (2817-3914 nt) into the multicloning site of eukaryotic expression vector pQM-NTag/Ai+(Quattromed Ltd) followed by deletion of intron. The pUCURR-6b, -11, -16 and -18 plasmids were cloned by inserting viral sequences containing the URR region of HPV6b (7292-101 nt), -11 (7022-94 nt), -16 (6361-282 nt) and -18 (6929-124 nt) into the multicloning site of pUC-19 plasmid. pMHE1-6b, -11, -16 and -18 vectors contained E6, E7 and E1 ORFs from HPV6b (102-2781 nt), -11 (102-2781 nt), -16 (83-2814 nt) or -18 (105-2887 nt) that were directed by CMV promoter in the pQM-NTag/Ai+vector with deleted intron and 3F12 epitope tag. Initiation codons for E6 and E7 oncogenes were deleted. The major splice donor site (AGGT) at the beginning of E1 ORFs was disrupted by inserting influenza hemagglutinin epitope tag (HA) inframe into the E1 coding sequence. The inserted HA tag had no effect on the E1 protein activities. Additional point mutation was introduced into the splicing acceptor site of HPV11 E1 ORF (2622 nt), (ACA-ACC), and this did not change the coding capacity. pUCHPV18 wt were cloned by inserting EcoRV-linearized HPV-18 genome (4670 nt within L2) into pUC19 SmaI site.
Cell Lines and Transfection
HeLa and SiHa cells were grown in Iscove's modified Dulbecco's medium (IMDM) supplemented with 10% fetal calf serum. Electroporation experiments were carried out as described by Ustav and Stenlund, 1991, using the Bio-Rad Gene Pulser II apparatus supplied with a capacitance extender (Bio-Rad Laboratories, USA). Capacitance was set to 975 mF and voltage to 220V in all experiments. Cells were plated onto 60 mm dishes and harvested at different time points.
Transient Replication Assays
Low-molecular-weight DNA was purified by alkaline lysis as described by Ustav and Stenlund, 1991. Total DNA was extracted from cells (FM Ausubel et al., 1998). DNA digested with appropriate enzymes was resolved in 0.5 or 0.8% agarose gel, blotted and hybridized with appropriate 32P-labeled probe generated by random priming (DecaLabel kit, Fermentas, Lithuania). The cellular sequences (SL1, SR2, SL1 and SL2) used in hybridization were amplified from SiHa genomic DNA with PCR using Taq polymerase and primers that were designed with the programs Primer3 (Rozen and Skaletsky, 2000) and GenomeTester (Andreson et al., 2006). Radioactive signals were quantified using ImageQuant software of PhosporImager SI (Molecular Dynamics, Amersham Biosciences, UK).
Immunoblotting
Total protein from an equal number of cells was separated by electrophoresis on 10% polyacrylamide-SDS gels and transferred to Immobilon-P membrane (Millipore, USA). Antibodies 3F10-HRP (Roche) and 4E4 were used to detect E1 and E2 proteins using the enhanced chemoluminescence detection kit (Amersham Biosciences).
Cell Sorting
For cell sorting, cells were cotransfected with pEGFP-N1 (Clonetech) and pUCHPV18 wt plasmids. Forty-eight hours after transfection, the transfected cells were sorted on the basis of EGFP fluorescence using the FACSDiva software and the FACSAria hardware (Becton Dickinson) equipped with a 13 mW argon ion laser set at 488 nm with a 530/30 nm filter. The purity of EGFP+cells, when reanalyzed, was 90±5%.
DIPS-PCR
DIPS-PCR assay was performed as described previously (Luft et al., 2001). The ds adapter was constituted from AS1 (5′-PO4-gatccaacgtgtaagtctg-NH2) (SEQ. ID NO. 1) and AL1 (5′-gggccatcagtcagcagtcgtagccggatccagacttacacgttg-3′) (SEQ. ID NO. 2) DNA oligos. The primers used in PCR were AP1 (5′-ggccatcagtcagcagtcgtag-3′) (SEQ. ID NO. 3) and S1 (5′. agggaatcccaatgaaggac-3′) (SEQ. ID NO. 4). PCR products were analyzed by 1.2% agarose gel electrophoresis followed by purification of the product of interest and sequence determination.
Number | Date | Country | Kind |
---|---|---|---|
P200700012 | Mar 2007 | EE | national |
This application is a national phase application pursuant to 35 U.S.C. §371 of International Application No. PCT/EE2008/000004, filed Mar. 27, 2008, which claims priority to Estonia Application No. P200700012, filed Mar. 28, 2007.
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/EE08/00004 | 3/27/2008 | WO | 00 | 6/17/2010 |